Drug intelligence / Profile preview

Juglans californica pollen

Development stage
Unknown
Lead developer
Greer Laboratories
Modality
Sublingual Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics, Subcutaneous Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics
Administration
Intradermal, Percutaneous, Subcutaneous
01

Overview

Juglans californica pollen is an allergenic extract derived from the pollen of the Juglans californica plant, also known as the California Black Walnut. [4, 5] It is marketed by Greer Laboratories, Inc. and was approved as a biologic (BLA101833) on September 15, 1981. [2] The product is indicated for the diagnosis (via skin testing) and treatment (via immunotherapy) of patients with immediate hypersensitivity allergies to California Black Walnut pollen. [2, 6] The mechanism of action involves modulating the body's immune response through cell-mediated immunity, leading to increased IgG production and desensitization to the allergen. [2] It is administered as a solution via intradermal, percutaneous, or subcutaneous routes. [2]

Brand names
California Black Walnut Pollen
Other names
Juglans californica pollen extractnon-standardized pollen allergenic extractSOUTHERN CALIFORNIA WALNUT POLLENCALIFORNIA BLACK WALNUT POLLEN EXTRACT

Beyond the preview

Go deeper on Juglans californica pollen.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Juglans californica pollen.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call